Nikolaos Ktenopoulos

Dr. Nikolaos Ktenopoulos

First Department of Cardiology, Hippocration General Hospital, Athens, Attikí, Greece
+1
orcid
MD | MSc Interventional Cardiology | PhD | Cardiology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Marios SagrisMarios Sagris
Marios Sagris
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
PTPanagiotis Theofilis
Panagiotis Theofilis
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
Odysseas KatsarosOdysseas Katsaros
Odysseas Katsaros
Dimitris TousoulisDimitris Tousoulis
Dimitris Tousoulis
Myocardial ischemia–reperfusion injury (MIRI) remains a challenge in the context of reperfusion procedures for myocardial infarction (MI). While early revascularization stands as the gold standard for mitigating myocardial injury, recent insights have illuminated the paradoxical role of reperfusion, giving rise to the phenomenon known as ischemia–reperfusion injury. This comprehensive review delves into the intricate pathophysiological pathways involved in MIRI, placing a particular focus on the pivotal role of endothelium. Beyond elucidating the molecular intricacies, we explore the diverse clinical manifestations associated with MIRI, underscoring its potential to contribute substantially to the final infarct size, up to 50%. We further navigate through current preventive approaches and highlight promising emerging strategies designed to counteract the devastating effects of the phenomenon. By synthesizing current knowledge and offering a perspective on evolving preventive interventions, this review serves as a valuable resource for clinicians and researchers engaged in the dynamic field of MIRI.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
Dimitrios TsiachrisDimitrios Tsiachris
Dimitrios Tsiachris
MDMaria Drakopoulou
Maria Drakopoulou
George TrantalisGeorge Trantalis
George Trantalis
GOGEORGIOS OIKONOMOU
GEORGIOS OIKONOMOU
KTKonstantinos Tsioufis
Konstantinos Tsioufis
This comprehensive review explores the incidence, pathophysiology, and management of atrial fibrillation (AF) following percutaneous closure of patent foramen ovale (PFO). Although AF is considered a common adverse event post PFO closure, its incidence, estimated at <5%, varies based on monitoring methods. The review delves into the challenging task of precisely estimating AF incidence, given subclinical AF and diverse diagnostic approaches. Notably, a temporal pattern emerges, with peak incidence around the 14th day after closure and a subsequent decline after the 45th day, mimicking general population AF trends. The pathophysiological mechanisms behind post PFO closure AF remain elusive, with proposed factors including local irritation, device‐related interference, tissue stretch, and nickel hypersensitivity. Management considerations encompass rhythm control, with flecainide showing promise, and anticoagulation tailored to individual risk profiles. The authors advocate for a personalized approach, weighing factors like age, comorbidities, and device characteristics. Notably, postclosure AF is generally considered benign, often resolving spontaneously within 45 days, minimizing thromboembolic risks. Further studies are required to refine understanding and provide evidence‐based guidelines.

Verified
Journal Article
Open access
PDF file
PKPaschalis Karakasis
Paschalis Karakasis
PTPanagiotis Theofilis
Panagiotis Theofilis
PVPanayotis K. Vlachakis
Panayotis K. Vlachakis
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
DPDimitrios Patoulias
Dimitrios Patoulias
Nikolaos FragakisNikolaos Fragakis
Nikolaos Fragakis
Atrial fibrillation (AF) is increasingly recognized not merely as an arrhythmia, but as a clinical manifestation of atrial cardiomyopathy (AtCM)—a progressive, multifaceted disease of the atrial myocardium involving structural, electrical, mechanical, and molecular remodeling. AtCM often precedes AF onset, sustains its perpetuation, and contributes to thromboembolic risk independently of rhythm status. Emerging evidence implicates diverse pathophysiological drivers of AtCM, including inflammation, epicardial adipose tissue, metabolic dysfunction, oxidative stress, ageing, and sex-specific remodeling. The NLRP3 inflammasome has emerged as a central effector in atrial inflammation and remodeling. Gut microbial dysbiosis, lipid dicarbonyl stress, and fibro-fatty infiltration are also increasingly recognized as contributors to arrhythmogenesis. AtCM is further linked to atrial functional valve regurgitation and adverse outcomes in AF. Therapeutically, substrate-directed strategies—ranging from metabolic modulation and immunomodulation to early rhythm control—offer promise for altering the disease trajectory. This review synthesizes mechanistic insights into AtCM and discusses emerging therapeutic paradigms that aim not merely to suppress arrhythmia but to modify the underlying substrate. Recognizing AF as a syndrome of atrial disease reframes management strategies and highlights the urgent need for precision medicine approaches targeting the atrial substrate.

10 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
PKPaschalis Karakasis
Paschalis Karakasis
PVPanayotis K. Vlachakis
Panayotis K. Vlachakis
PTPanagiotis Theofilis
Panagiotis Theofilis
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
DPDimitrios Patoulias
Dimitrios Patoulias
Nikolaos FragakisNikolaos Fragakis
Nikolaos Fragakis
Atrial fibrillation (AF) is increasingly recognized as the clinical manifestation of an underlying atrial disease process rather than a purely electrical disorder. This evolving paradigm has given rise to the concept of atrial cardiomyopathy (AtCM), encompassing structural, electrical, contractile, and molecular remodeling of the atrial myocardium that contributes to AF initiation, maintenance, and progression. Although consensus definitions of AtCM now exist, its integration into clinical practice remains limited, with AF management still largely guided by arrhythmic patterns rather than substrate characterization. This review synthesizes current diagnostic strategies for AtCM within the context of AF, emphasizing a multimodal approach. We outline advances in cardiac imaging—including echocardiography, cardiac magnetic resonance, and computed tomography—for detailed assessment of atrial morphology, function, and fibrosis. Electroanatomic mapping is discussed as a key invasive tool for substrate localization, while electrocardiographic indices such as P-wave morphology and dispersion serve as accessible surrogates of electrical remodeling. In parallel, we examine the role of circulating biomarkers and emerging genomic, transcriptomic, and epigenomic markers in refining disease phenotyping. Despite promising progress, significant challenges remain. Standardization of imaging protocols, validation of biomarker thresholds, and integration of artificial intelligence tools are needed to enhance clinical utility. A diagnostic framework informed by atrial substrate assessment may support more tailored therapeutic decision-making in AF. Future research should prioritize the harmonization of diagnostic criteria and explore how substrate profiling in AF may refine risk stratification and improve clinical outcomes.

Verified
Journal Article
Open access
PDF file
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
Marios SagrisMarios Sagris
Marios Sagris
MGMaria E. Gerogianni
Maria E. Gerogianni
KPKonstantinos Pamporis
Konstantinos Pamporis
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
Dimitris TousoulisDimitris Tousoulis
Dimitris Tousoulis
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is regarded as a liver manifestation of metabolic syndrome. It is linked to insulin resistance, obesity, and diabetes mellitus, all of which increase the risk of cardiovascular complications. Endothelial dysfunction (EnD) constitutes the main driver in the progression of atherosclerosis and coronary artery disease (CAD). Several pathophysiological alterations and molecular mechanisms are involved in the development of EnD in patients with NAFLD. Our aim is to examine the association of NAFLD and CAD with the parallel assessment of EnD, discussing the pathophysiological mechanisms and the genetic background that underpin this relationship. This review delves into the management of the condition, exploring potential clinical implications and available medical treatment options to facilitate the deployment of optimal treatment strategies for these patients.

Verified
Journal Article
Open access
PDF file
PKPaschalis Karakasis
Paschalis Karakasis
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
KPKonstantinos Pamporis
Konstantinos Pamporis
Marios SagrisMarios Sagris
Marios Sagris
SSStergios Soulaidopoulos
Stergios Soulaidopoulos
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Background: Real-world data show limited utilization of direct oral anticoagulants (DOACs) in obese patients (body mass index [BMI] ≥ 30 kg/m2) due to concerns regarding their efficacy and safety in this demographic. Aim: This review aimed to consolidate current evidence on the efficacy and safety of DOACs versus warfarin in obese patients with non-valvular atrial fibrillation (AF) or venous thromboembolism (VTE). The primary efficacy outcome assessed a composite of all-cause mortality, stroke, systemic embolism (SE), and myocardial infarction (MI). Methods: A systematic search was conducted in MEDLINE, SCOPUS, and Cochrane databases from inception to December 28, 2023. Data were synthesized using random-effects meta-analysis. Results: A total of 35 studies involving 434,320 participants were analyzed. DOAC use was associated with a significant reduction in the risk of the composite outcome (RR = 0.80, 95% CI [0.65, 0.98], I2 = 95%), hemorrhagic stroke (RR = 0.58, 95% CI [0.38, 0.88], I2 = 92%), major bleeding (RR = 0.76, 95% CI [0.63, 0.92], I2 = 94%), gastrointestinal bleeding (RR = 0.59, 95% CI [0.49, 0.72], I2 = 88%), and intracranial bleeding (RR = 0.45, 95% CI [0.34, 0.60], I2 = 44%) compared to warfarin. A non-significant benefit of DOACs was observed for all-cause mortality, MI, the composite of stroke or SE, ischemic stroke, SE, VTE, and minor bleeding compared to warfarin. Subgroup analysis indicated no significant effect modification based on the indication for anticoagulation or study design. Conclusions: DOACs demonstrated a favorable efficacy and safety profile in obese individuals compared to warfarin.